Core Viewpoint - The article discusses the strategic moves of BGI Genomics, including the sale of its overseas subsidiary Complete Genomics and the acquisition of companies specializing in spatial genomics and nanopore sequencing technology, aiming to enhance its technological capabilities and market position in the competitive genomics industry [1][3][21]. Group 1: Capital Actions - In early 2026, BGI Genomics announced the sale of Complete Genomics for approximately $50 million to Swiss Rockets AG, while retaining some core technology licensing agreements [1][4]. - The company also approved the acquisition of Shenzhen BGI Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xifeng Technology Co., Ltd. for a total of about 366 million yuan, focusing on spatial genomics and nanopore sequencing technologies [3][21]. Group 2: Business Structure and Financial Performance - BGI Genomics' core business has long centered around the DNBSEQ short-read sequencing platform, which is primarily used in genomics, transcriptomics, and clinical testing [5]. - In the first half of 2025, the company reported revenues of 1.114 billion yuan, with full-length sequencing business revenue accounting for approximately 80% [6]. - The sales structure indicates a typical life science tools business model, where equipment sales drive reagent consumption, despite a 23% decline in equipment revenue year-on-year [6]. Group 3: Technological Landscape - The global genomics industry has formed three main technological routes: short-read sequencing, long-read sequencing, and spatial genomics, each addressing different biological questions [9][10]. - BGI Genomics' acquisitions align with these technological directions, enhancing its capabilities in spatial genomics and long-read sequencing [8][13]. Group 4: Strategic Implications - The acquisition of Shenzhen BGI Sanjian Qifa Technology Co., Ltd. focuses on Stereo-seq spatial genomics technology, which has been widely applied in brain science and tumor research [15][16]. - The acquisition of Hangzhou BGI Xifeng Technology Co., Ltd. emphasizes nanopore single-molecule sequencing technology, which complements existing short-read technologies [17][18]. - These strategic moves reflect a broader trend among Chinese life science tool companies to build comprehensive technological ecosystems, moving from single-platform competition to integrated life science tool ecosystems [21][22].